NCT05062421Recruiting
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
Source: ClinicalTrials.gov · Last updated 17 Nov 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 540 (estimated)
- First submitted
- 10 Sept 2021
- Start date
- 1 Apr 2021
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT05062421
What you commit to
- Study type: Observational
- Planned participants: 540
- From 1 Apr 2021 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
- Patients in whom more than 50% of the variables to be collected are missing in the data collection.
Who the study is looking for
- Patients aged ≥18 years.
- With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
- Who have received at least one of the doses of the study drugs.
- In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
- With at least two complete evaluations (baseline and final) of clinical variables.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Virgen Macarena Coordinator of this site? Confirm its status | Seville | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.